对超重和肥胖的成年人进行内镜减肥手术:系统性审查和网络元分析
Jing Zhu1,2, Yongqi Yan2, Xinyi Qiu2
1Department of Endocrinology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
International journal of obesity (2005)
|November 11, 2024
概括
内镜减肥手术 (EBS) 提供减肥解决方案. laparoscopic袖子胃切除术 (LSG) 显示出最高的疗效,而内镜袖子胃整形术 (ESG) 为肥胖症治疗提供了卓越的安全性和代谢益处.
科学领域:
- 腹部外科 腹部外科
- 最少侵入性手术的方法
- 肥胖管理 肥胖管理
背景情况:
- 内镜减肥手术 (EBS) 是肥胖症的新兴治疗类别.
- 针对腹腔镜袖子胃切除术 (LSG) 的各种EBS手术的比较疗效和安全数据对于临床决策至关重要.
研究的目的:
- 系统地比较不同内镜减肥手术 (EBS) 与腹腔镜袖子胃切除术 (LSG) 的疗效,安全性和代谢并发症率.
主要方法:
- 进行了系统性审查和频率网络元分析 (NMA).
- 搜索范围包括PubMed,科学网和科克兰图书馆 (2017年1月至2022年12月).
- 包括18项与766,135名参与者进行的试验,比较了LSG,内镜套胃形成术 (ESG),非调节性胃内气球 (NIB),BioEnterics胃内气球 (BIB) 和调节性胃内气球 (AIB).
主要成果:
- laparoscopic 袖子胃切除术 (LSG) 在减肥方面表现出最高的疗效.
- 内镜套管胃形成术 (ESG) 在六个月内显示出与LSG相比的体重减轻 (SMD -0.31),并且具有最低的不良事件发生率.
- 与LSG相比,其他程序如NIB (SMD -0.49),AIB (SMD -0.41) 和BIB显示体重减轻较少.
结论:
- 内镜套管胃形成术 (ESG) 是一种安全有效的微创手术,用于治疗超重和肥胖症.
- 12个月的ESG疗效超过了不可调节的胃内气球 (NIB).
- 由于其对脂质代谢的积极影响,ESG为心血管和肝脏健康提供了显著的保护性益处.
相关概念视频
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Inflammatory Bowel Disease V: Surgical Management
917
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
917
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324


